GILEAD SCIENCES, INC. for GILEAD SCIENCES INC
What was lobbied
10 issue areas, each in the filer's own words, with who lobbied on it and where.
Veterans VET
Education related to Hepatitis C. FY18 Military Construction VA Appropriations bill.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHARLES M. CLAPTON New | — |
| DAVID PULLIAM | — |
Copyright/Patent/Trademark CPT
Technology transfer, patent rights and funding, patent reform legislation. Issues related to pharmaceuticals and intellectual property protection.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHARLES M. CLAPTON New | — |
| DAVID PULLIAM | — |
Health Issues HCR
Pending healthcare legislation and potential impact on the biopharmaceutical industry. Ryan White Care Act reauthorization; Hepatitis C policy; PEPFAR reauthorization; HIV/AIDS research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV and HIV portfolio.Funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program; implementation of section 340B drug discount program. Prison population and hepatitis C.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHARLES M. CLAPTON New | — |
| KACY HUTCHISON | — |
| DAVID PULLIAM | — |
Budget/Appropriations BUD
Funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHARLES M. CLAPTON New | — |
| KACY HUTCHISON | — |
| DAVID PULLIAM | — |
Medicare/Medicaid MMM
Ryan White Care Act reauthorization; Hepatitis C policy; HIV/AIDS research, testing and treatment. HCV testing, screening and linkage to care programs. Federal program coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products. Coverage of pharmaceuticals, cost-sharing and other access issues; issues related to coverage and reimbursement of pharmaceuticals.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHARLES M. CLAPTON New | — |
| KACY HUTCHISON | — |
| DAVID PULLIAM | — |
Foreign Relations FOR
Issues related to pharmaceuticals and international finance for health services. Access to medicines and intellectual property protection.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHARLES M. CLAPTON New | — |
| KACY HUTCHISON | — |
| DAVID PULLIAM | — |
Trade (domestic/foreign) TRD
International trade and protection of intellectual property
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHARLES M. CLAPTON New | — |
| KACY HUTCHISON | — |
| DAVID PULLIAM | — |
Taxation/Internal Revenue Code TAX
Issues related to international and corporate tax reform. The House Republican Tax Reform Blueprint, President Trump's Tax Reform Principles, the Senate's tax reform efforts, and the Joint Statement on Tax Reform.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHARLES M. CLAPTON New | — |
| KACY HUTCHISON | — |
| DAVID PULLIAM | — |
Pharmacy PHA
Coverage of pharmaceuticals, cost-sharing and other access issues. Issues related to coverage and reimbursement of pharmaceuticals; issues related to Medicare, Medicaid, and ACA implementation; FDA issues and 340B.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHARLES M. CLAPTON New | — |
| KACY HUTCHISON | — |
| DAVID PULLIAM | — |
Indian/Native American Affairs IND
Education related to Hepatitis C in American Indian population.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHARLES M. CLAPTON New | — |
| KACY HUTCHISON | — |
| DAVID PULLIAM | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.